A Phase 2 interventional study of G-CSF plus plerixafor in Autologous Stem Cell Transplantation, sponsored by Genzyme, a Sanofi Company. Completed at 8 sites in United States. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2014-03-13.
Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma — 1 open to participants now, 1 under way, 1 of them phase 3. Granulocyte Colony-Stimulating Factor · Multiple Myeloma.
Among the 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma, this one is the 5th largest by enrollment, is one of 5 that started in 2005, is one of 17 in phase 2, and was the 8th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →1 of the 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma is open now, in 1 country. Recruiting first, the newest first:
Guangzhou Gloria Biosciences Co., Ltd. · Sites in China
Ages 18–78
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 78 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 18 · Phase 3 3 · Phase 4 1
First in 1999; this study’s year is marked. 5 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 38 across the 28 interventional studies. Of the 27 that completed or were terminated, 15 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genzyme, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Genzyme, a Sanofi Company is the lead sponsor of 308 studies on the registry; 5 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 19 (76%) have results posted.
39 studies in Multiple Myeloma by Sanofi: 3 open now, 8 under way, 3 of them phase 3. Of 30 finished, 12 (40%) have results posted.
Among the 39 studies in Multiple Myeloma by Sanofi, this one is the 11th largest by enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2005, is one of 14 in phase 2, and was the 6th registered.
Sanofi’s Multiple Myeloma studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 39 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
This study evaluates the safety, efficacy, and pharmacokinetics (PK) of plerixafor given in addition to granulocyte-colony stimulating factor (G-CSF) for collection of peripheral blood stem cells (PBSCs) for autologous transplantation in patients who would benefit from an autologous stem cell transplant but have failed previous collections or collection attempts with a mobilization regimen of G-CSF alone, chemotherapy and G-CSF, or any other conventional therapy including cytokines, chemotherapy and cytokines and bone marrow harvests.
The only change to standard of care of a mobilization regimen that includes G-CSF is the addition of a dose of AMD3100 (plerixafor) on the evening prior to each day of apheresis.
Efficacy outcomes include quantification of CD34+ cells in the apheresis product and assessment of successful polymorphonuclear leukocyte (PMN) and platelet (PLT) engraftment after transplantation. PK outcomes include analysis of repeated doses of plerixafor.
This is a Phase 2, multicenter, prospective, open-label study. Once 70 patients have enrolled, subsequent patients enrolled should have a diagnosis of lymphoma. Patients who would benefit from an autologous stem cell transplant, who have failed previous collections or collection attempts with a mobilization regimen of granulocyte colony-stimulating factor (G-CSF) alone, chemotherapy and G-CSF, or any other conventional therapy including cytokines, chemotherapy and cytokines and bone marrow harvests, and who meet the inclusion/exclusion criteria are eligible to receive plerixafor as outlined in this protocol. The only change to standard of care of a mobilization regimen that includes G-CSF is the addition of a dose of plerixafor on the evening prior to each day of apheresis.
Patients will undergo mobilization with G-CSF (10 µg/kg) for 4 days. On Day 4, plerixafor (240 µg/kg) will be administered in the evening prior to the first apheresis and each subsequent evening prior to apheresis thereafter, such that there is a 10 to 11 hour interval between dosing and the initiation of apheresis. Patients will continue to receive G-CSF on each day of apheresis. Patients will undergo a minimum of 2 and a maximum of 7 aphereses or until ≥2*10\^6 CD34+ cells/kg are collected, whichever occurs first. In addition, the mobilization of NHL tumor cells and the pharmacokinetics of repeat doses of plerixafor will be examined.
After the last apheresis has been completed, or after the patient has collected ≥2*10\^6 CD34+ cells/kg, he/she will be treated with high-dose chemotherapy in preparation for transplantation. Patients will be transplanted with cells obtained from the G-CSF with plerixafor mobilization regimen. In the event that the minimum number of ≥2*10\^6 cells for transplantation are not obtained from the first mobilization with plerixafor, cells may be retained and pooled for transplantation with those from a second mobilization with plerixafor (or from prior mobilization with other agents), at the investigator's discretion. If a second mobilization with plerixafor is attempted, a minimum rest interval of one week should be allowed between the last apheresis of the first regimen and the first dose of G-CSF of the second. The number of CD34+ cells mobilized in the peripheral blood (PB), collected in the apheresis product, and the number of apheresis sessions performed will be measured. Success of the transplantation will be evaluated by the time to engraftment of polymorphonuclear leukocytes (PMN) and platelets (PLT). Participants will be assessed for durability of their transplant for 12 months after transplantation.
This study was previously posted by AnorMED, Inc. In November 2006, AnorMED, Inc. was acquired by Genzyme Corporation. Genzyme Corporation is the sponsor of the trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: G-CSF plus plerixafor
Drug pages: Granulocyte Colony-Stimulating Factor · Plerixafor
Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 7 aphereses or until ≥ 2\*10\^6 CD34+ cells/kg were collected.
Also known as: AMD3100, Mozobil
Overall Participant Counts Summarizing Adverse Events (AEs) During the Treatment Period
Number of participants with adverse events (AEs) collected from Day 1 (start of G-CSF mobilization) to the day before starting chemotherapy. AEs were graded by the investigator using the World Health Organization (WHO) Adverse Event Grading Scale and were assessed for severity (mild, moderate, severe, life-threatening) and relatedness to study treatment (5 point scale from 'not related' to 'definitely related').
Time frame: Day 1 to approximately day 38
Proportion of Participants Who Achieved ≥2*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF
Proportion of participants who reached the target of at least 2\*10\^6 CD34+ cells/kg collected during up to 7 aphereses.
Time frame: Day 5 to Day 11 (up to 7 apheresis)
Proportion of Participants Who Achieved ≥5*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF
Proportion of participants who reached the target of at least 5\*10\^6 CD34+ cells/kg collected during up to 7 apheresis.
Time frame: Day 5 to Day 11 (up to 7 aphereses)
Median Number of Days to Polymorphonuclear Leukocyte (PMN) Engraftment
The number of days from transplantation to successful engraftment as measured by PMN \>=0.5\*10\^9 /L for 3 days or \>=1.0\*10\^9 /L for 1 day.
Time frame: approximately 2 months (1 month post transplant)
Median Number of Days to Platelet (PLT) Engraftment
The number of days from transplantation to successful engraftment as measured by platelet value of \>=20\*10\^9/L for 7 days without transfusion.
Time frame: Approximately 2 months (1 month post transplant)
Number of Participants With Durable Engraftment 12 Months After Autologous Transplantation
The number of participants maintaining a durable graft 12 months after transplantation. A durable graft was defined as maintenance of normal blood counts: PLT \>50\*10\^9/L without transfusion for at least 2 weeks prior to the visit; hemoglobin level \>= 10 g/dL with no erythropoietin or transfusions for at least 1 month prior to the visit; and absolute neutrophil count (ANC) \> 1,000 (1\*10\^9/L) with no G-CSF for at least 1 week prior to the visit.
Time frame: Approximately 13 months (12 months post transplant )
Number of Participants With Non-Hodgkin's Lymphoma (NHL) Who Had Evidence of Tumor Cell Mobilization After G-CSF or Plerixafor Administration
The number of participants with Bcl2 translocation in post-treatment samples.
Time frame: Up to Day 7
Number of Participants Who Achieved ≥2*10^6 CD34+ Cells/kg Collected During Both Courses of Treatment With Plerixafor and G-CSF
Number of participants who had at least 2\*10\^6 CD34+ cells/kg collected by apheresis during both the first and the second courses of treatment together.
Time frame: Day 5 up to Month 6 (up to 7 aphereses in each course of treatment)
Number of Participants Who Achieved ≥5*10^6 CD34+ Cells/kg Collected During Both Courses of Treatment With Plerixafor and G-CSF
Number of participants who had at least 5\*10\^6 CD34+ cells/kg collected by apheresis during both the first and the second courses of treatment together.
Time frame: Day 5 up to Month 6 (up to 7 aphereses in each course of treatment)
Maximum Observed Plasma Concentration (Cmax) on Day 4
Maximum plasma concentration (Cmax) of plerixafor following daily doses of 240 µg/kg plerixafor, determined directly from the concentration-time data.
Time frame: Day 4 (following first plerixafor administration)
Maximum Observed Plasma Concentration (Cmax) on Day 7
Maximum plasma concentration (Cmax) of plerixafor following daily doses of 240 µg/kg plerixafor, determined directly from the concentration-time data.
Time frame: Day 7 (following fourth plerixafor administration)
Time to Maximum Plasma Concentration (Tmax) on Day 4
Time to maximum plasma concentration (Tmax) of plerixafor following daily doses of 240 µg/kg plerixafor, determined directly from the concentration-time data
Time frame: Day 4 (following first plerixafor administration)
Time to Maximum Plasma Concentration (Tmax) on Day 7
Time to maximum plasma concentration (Tmax) of plerixafor following daily doses of 240 µg/kg plerixafor, determined directly from the concentration-time data
Time frame: Day 7 (following fourth plerixafor administration)
Area Under the Steady-state Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Sample (AUC0-last) on Day 4
Area under the steady-state plasma concentration time curve from time zero to the last quantifiable sample after each plerixafor daily dose of 240 µg/kg, determined using the linear trapezoidal rule.
Time frame: Days 4 -5 (following first plerixafor administration)
Area Under the Steady-state Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Sample (AUC0-last) on Day 7
Area under the steady-state plasma concentration time curve from time zero to the last quantifiable sample after each plerixafor daily dose of 240 µg/kg, determined using the linear trapezoidal rule.
Time frame: Days 7-8 (following fourth plerixafor administration)
| Milestone | G-CSF Plus Plerixafor |
|---|---|
| Started | 100 |
| Number of participants treated | 100 |
| Number of participants transplanted | 87 |
| Completed | 68 |
| Not completed | 32 |
| Withdrew: Failed to mobilize - no transplant | 8 |
| Withdrew: Did not go on to transplant | 5 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Death | 16 |
Number of participants with adverse events (AEs) collected from Day 1 (start of G-CSF mobilization) to the day before starting chemotherapy. AEs were graded by the investigator using the World Health Organization (WHO) Adverse Event Grading Scale and were assessed for severity (mild, moderate, severe, life-threatening) and relatedness to study treatment (5 point scale from 'not related' to 'definitely related').
| Participants | Non-Hodgkin's Lymphoma | Hodgkin's Disease | Multiple Myeloma | Other Cancers | All Patients |
|---|---|---|---|---|---|
| Participants Reporting At Least 1 AE | 65 | 20 | 9 | 3 | 97 |
| Adverse Events by Severity -Mild | 42 | 12 | 7 | 1 | 62 |
| Adverse Events by Severity -Moderate | 18 | 8 | 1 | 0 | 27 |
| Adverse Events by Severity -Severe | 5 | 0 | 1 | 2 | 8 |
| Adverse Events by Severity -Life Threatening | 0 | 0 | 0 | 0 | 0 |
| AE Relationship to Study Drug -Not Related | 10 | 4 | 4 | 0 | 18 |
| AE Relationship to Study Drug-Probably Not Related | 8 | 2 | 1 | 0 | 11 |
| AE Relationship to Study Drug -Possibly Related | 16 | 4 | 1 | 0 | 21 |
| AE Relationship to Study Drug -Probably Related | 22 | 2 | 2 | 1 | 27 |
| AE Relationship to Study Drug -Definitely Related | 9 | 8 | 1 | 2 | 20 |
Proportion of participants who reached the target of at least 2\*10\^6 CD34+ cells/kg collected during up to 7 aphereses.
| Proportion of Participants | Non-Hodgkin's Lymphoma | Hodgkin's Disease | Multiple Myeloma | Other Cancers | All Patients |
|---|---|---|---|---|---|
| Proportion of Participants Who Achieved ≥2*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF | .773 | .714 | 1.00 | .667 | .780 |
The number of days from transplantation to successful engraftment as measured by PMN \>=0.5\*10\^9 /L for 3 days or \>=1.0\*10\^9 /L for 1 day.
| Days | Non-Hodgkin's Lymphoma | Hodgkin's Disease | Multiple Myeloma | Other Cancers | All Patients |
|---|---|---|---|---|---|
| Median Number of Days to Polymorphonuclear Leukocyte (PMN) Engraftment | 12.0 (2.0 to 19.0) | 12.0 (11.0 to 15.0) | 13.0 (9.0 to 16.0) | 10.0 (7.0 to 13.0) | 12.0 (2.0 to 19.0) |
The number of days from transplantation to successful engraftment as measured by platelet value of \>=20\*10\^9/L for 7 days without transfusion.
| Days | Non-Hodgkin's Lymphoma | Hodgkin's Disease | Multiple Myeloma | Other Cancers | All Patients |
|---|---|---|---|---|---|
| Median Number of Days to Platelet (PLT) Engraftment | 21.0 (7.0 to 88.0) | 21.0 (15.0 to 81.0) | 19.0 (16.0 to 24.0) | 26.0 (3.0 to 49.0) | 21.0 (3.0 to 88.0) |
The number of participants maintaining a durable graft 12 months after transplantation. A durable graft was defined as maintenance of normal blood counts: PLT \>50\*10\^9/L without transfusion for at least 2 weeks prior to the visit; hemoglobin level \>= 10 g/dL with no erythropoietin or transfusions for at least 1 month prior to the visit; and absolute neutrophil count (ANC) \> 1,000 (1\*10\^9/L) with no G-CSF for at least 1 week prior to the visit.
| Participants | Non-Hodgkin's Lymphoma | Hodgkin's Disease | Multiple Myeloma | Other Cancers | All Patients |
|---|---|---|---|---|---|
| Number of Participants With Durable Engraftment 12 Months After Autologous Transplantation | 44 | 14 | 7 | — | 65 |
Proportion of participants who reached the target of at least 5\*10\^6 CD34+ cells/kg collected during up to 7 apheresis.
| Proportion of Participants | Non-Hodgkin's Lymphoma | Hodgkin's Disease | Multiple Myeloma | Other Cancers | All Patients |
|---|---|---|---|---|---|
| Proportion of Participants Who Achieved ≥5*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF | 0.288 | 0.429 | 0.70 | 0.667 | 0.37 |
The number of participants with Bcl2 translocation in post-treatment samples.
No measurements were reported for this outcome.
Number of participants who had at least 2\*10\^6 CD34+ cells/kg collected by apheresis during both the first and the second courses of treatment together.
| Participants | Non-Hodgkin's Lymphoma | Hodgkin's Disease | Multiple Myeloma | Other Cancers | All Patients |
|---|---|---|---|---|---|
| Number of Participants Who Achieved ≥2*10^6 CD34+ Cells/kg Collected During Both Courses of Treatment With Plerixafor and G-CSF | 54 | 18 | 10 | 2 | 84 |
Number of participants who had at least 5\*10\^6 CD34+ cells/kg collected by apheresis during both the first and the second courses of treatment together.
| Participants | Non-Hodgkin's Lymphoma | Hodgkin's Disease | Multiple Myeloma | Other Cancers | All Patients |
|---|---|---|---|---|---|
| Number of Participants Who Achieved ≥5*10^6 CD34+ Cells/kg Collected During Both Courses of Treatment With Plerixafor and G-CSF | 21 | 9 | 7 | 2 | 39 |
Maximum plasma concentration (Cmax) of plerixafor following daily doses of 240 µg/kg plerixafor, determined directly from the concentration-time data.
| ng/mL | PK Subpopulation |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) on Day 4 | 796 ± 305 |
Maximum plasma concentration (Cmax) of plerixafor following daily doses of 240 µg/kg plerixafor, determined directly from the concentration-time data.
| ng/mL | PK Subpopulation |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) on Day 7 | 894 ± 227 |
Time to maximum plasma concentration (Tmax) of plerixafor following daily doses of 240 µg/kg plerixafor, determined directly from the concentration-time data
| Hours | PK Subpopulation |
|---|---|
| Time to Maximum Plasma Concentration (Tmax) on Day 4 | 0.500 (0.0500 to .750) |
Time to maximum plasma concentration (Tmax) of plerixafor following daily doses of 240 µg/kg plerixafor, determined directly from the concentration-time data
| Hours | PK Subpopulation |
|---|---|
| Time to Maximum Plasma Concentration (Tmax) on Day 7 | 0.500 (0.417 to 0.600) |
Area under the steady-state plasma concentration time curve from time zero to the last quantifiable sample after each plerixafor daily dose of 240 µg/kg, determined using the linear trapezoidal rule.
| ng*h/mL | PK Subpopulation |
|---|---|
| Area Under the Steady-state Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Sample (AUC0-last) on Day 4 | 4578 ± 1715 |
Area under the steady-state plasma concentration time curve from time zero to the last quantifiable sample after each plerixafor daily dose of 240 µg/kg, determined using the linear trapezoidal rule.
| ng*h/mL | PK Subpopulation |
|---|---|
| Area Under the Steady-state Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Sample (AUC0-last) on Day 7 | 5496 ± 1339 |
Collected over First day of G-CSF mobilization to the day prior to chemotherapy/ablative treatment in preparation for the first transplant. This timeframe includes G-CSF and plerixafor administration, and the rest period.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Non-Hodgkin's Lymphoma | — | 4/66 (6.1%) | 64/66 (97%) |
| Hodgkin's Disease | — | 0/21 (0%) | 20/21 (95.2%) |
| Multiple Myeloma | — | 1/10 (10%) | 9/10 (90%) |
| Other Cancers | — | 1/3 (33.3%) | 3/3 (100%) |
| Event | Non-Hodgkin's Lymphoma | Hodgkin's Disease | Multiple Myeloma | Other Cancers |
|---|---|---|---|---|
| Intestinal obstructionGastrointestinal disorders | 0/66 | 0/21 | 0/10 | 1/3 |
| AnxietyPsychiatric disorders | 0/66 | 0/21 | 1/10 | 0/3 |
| Atrial fibrillationCardiac disorders | 1/66 | 0/21 | 0/10 | 0/3 |
| PancreatitisGastrointestinal disorders | 1/66 | 0/21 | 0/10 | 0/3 |
| Catheter site infectionInfections and infestations | 1/66 | 0/21 | 0/10 | 0/3 |
| Central line infectionInfections and infestations | 1/66 | 0/21 | 0/10 | 0/3 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 1/66 | 0/21 | 0/10 | 0/3 |
| Event | Non-Hodgkin's Lymphoma | Hodgkin's Disease | Multiple Myeloma | Other Cancers |
|---|---|---|---|---|
| FatigueGeneral disorders | 28/66 | 8/21 | 4/10 | 2/3 |
| Injection site painGeneral disorders | 2/66 | 0/21 | 0/10 | 2/3 |
| Injection site pruritusGeneral disorders | 5/66 | 0/21 | 0/10 | 2/3 |
| HypokalaemiaMetabolism and nutrition disorders | 13/66 | 2/21 | 2/10 | 2/3 |
| DiarrhoeaGastrointestinal disorders | 21/66 | 7/21 | 4/10 | 0/3 |
| NauseaGastrointestinal disorders | 15/66 | 6/21 | 3/10 | 1/3 |
| VomitingGastrointestinal disorders | 5/66 | 2/21 | 0/10 | 1/3 |
| Catheter site painGeneral disorders | 4/66 | 1/21 | 2/10 | 1/3 |
| Injection site erythemaGeneral disorders | 18/66 | 6/21 | 2/10 | 1/3 |
| Breath sounds abnormalInvestigations | 0/66 | 0/21 | 0/10 | 1/3 |
| Age, Continuous(years) | Non-Hodgkin's Lymphoma | Hodgkin's Disease | Multiple Myeloma | Other Cancers | Total |
|---|---|---|---|---|---|
| Mean | 57.0 ± 10.0 | 45.6 ± 15.5 | 62.6 ± 11.3 | 32.7 ± 28.9 | 54.4 ± 13.6 |
| Sex: Female, Male(Participants) | Non-Hodgkin's Lymphoma | Hodgkin's Disease | Multiple Myeloma | Other Cancers | Total |
|---|---|---|---|---|---|
| Female | 29 | 10 | 5 | 1 | 45 |
| Male | 37 | 11 | 5 | 2 | 55 |
| Race/Ethnicity, Customized(participants) | Non-Hodgkin's Lymphoma | Hodgkin's Disease | Multiple Myeloma | Other Cancers | Total |
|---|---|---|---|---|---|
| Caucasian | 60 | 17 | 9 | 3 | 89 |
| Black or African American | 3 | 1 | 1 | 0 | 5 |
| Asian | 2 | 1 | 0 | 0 | 3 |
| Hispanic/Latino | 1 | 2 | 0 | 0 | 3 |
The record gives a start of Oct 2005, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2010, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Granulocyte Colony-Stimulating Factor · Plerixafor